Kosin Med J.  2014 Dec;29(2):99-106. 10.7180/kmj.2014.29.2.99.

Antenatal Magnesium Sulfate for Neuroprotective Effects In Preterm Infants

• Oh YL

• KMID: 2308494
• DOI: http://doi.org/10.7180/kmj.2014.29.2.99

Abstract

Fetal or neonatal brain injury can result in lifelong neurologic disability. Although survival rates for preterm infants have increased dramatically with the advent of modern perinatal and neonatal intensive care, but the rates of neurologic abnormalities in survivors, particularly motor disorders such as cerebral palsy, have not diminished. Antenatal magnesium sulfate may reduce the rates of cerebral palsy in survivors of preterm birth. There are five randomized controlled trials of magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation which have reported neurological outcomes for the child. From meta-analysis of these randomized trials, the rate of cerebral palsy was reduced by magnesium sulfate (RR, 0.69; 95% CI, 0.54-0.87; five trials; 6,145 infants) as did the moderate/severe cerebral palsy incidence (RR, 0.64; 95% CI, 0.44-0.92; three trials; 4387 infants). There was no statistically significant difference between the rates of neonatal adverse outcomes of the magnesium administration group and the control group. In most prospective randomized studies, no significant difference in the severe mother-side side effects between the magnesium sulfate administration group and the control group. Antenatal magnesium sulfate therapy is neuroprotective against motor dysfunction in offspring for the preterm infant; however the possibility of an increase in the fetal or neonatal death rate was not completely excluded.

Keyword

Cerebral Palsy; Magnesium Sulfate; Mortality; Neroprotection; preterm birth

MeSH Terms

Brain Injuries
Cerebral Palsy
Child
Female
Humans
Incidence
Infant, Newborn
Infant, Premature*
Intensive Care, Neonatal
Magnesium
Magnesium Sulfate*
Mortality
Neuroprotective Agents*
Pregnancy
Premature Birth
Survival Rate
Survivors
Magnesium
Magnesium Sulfate
Neuroprotective Agents

Reference

1.American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists'Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013. 122:1122.

2.Kuban K., Leviton A., Pagano M., Fenton T., Strasfeld R., Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. Journal of Child Neurology. 1992. 7:70–6.

3.Nelson KB., Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics. 1995. 95:263–9.

4.Mittendorf RS., Dambrosia J., Pryde PG., Lee KS., Gianopoulos JG., Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002. 186:1111–8.

5.Scudiero R: Khoshnood B., Pryde PG., Lee KS., Wall S., Mittendorf R. Perinatal death and tocolytic magnesium sulfate. Obstet Gynecol. 2000. 96:178–82.

6.Kimberlin DF., Hauth JC., Goldenberg RL., Bottoms SF., lams JD., Mercer B, et al. The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants. Am J Perinatol. 1998. 15:635–41.

7.Farkouh LJ., Thorp JA., Jones PG., Clark RH., Knox GE. Antenatal magnesium exposure and neonatal demise. Am J Obstet Gynecol. 2001. 185:869–72.

8.Marret S: Gres sens P., Gadisseux JF., Evrard P. Prevention by magnesium of excitotoxic neuronal death in the developing brain: an animal model for clinical intervention studies. Dev Med Child Neurol. 1995. 37:473–84.

9.Marret S: Doyle LW., Crowther CA: Middleton P. Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin Fetal Neonatal Med. 2007. 2:311–7.

10.Turkyilmaz C., Turkyilmaz Z., Atalay Y5., Soylemezoglu F., Celasun B. Magnesium pretreatment reduces neuronal apoptosis in newborn rats in hypoxiaeischemia. Brain Res. 2002. 955:133–7.

11.Choi DW., Maulucci-Gedde M: Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1967. 7:357–68.

12.Marinov MB., Harbaugh KS., Hoopers PJ, et al. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996. 85:117–24.

13.Shogi T: Miyamoto A., Ishiguro S: Nishio A. Enhanced release of IL-lbeta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-Mg (2J)) medium. Magnes Res. 2003. 16:111–9.

14.Ovbiagele B: Kidwell CS., Starkman S: Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003. 3:9–20.

15.MacDonald RL., Curry DJ., Aihara Y., Zhang ZD., Jahromi BS., Yassari R. Magnesium and experimental vasospasm. J Neurosurg. 2004. 100:106–10.

16.Mittendorf R., Dambrosia J., Pryde PG., Lee KS., Gianopoulos JG., Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002. 186:1111–8.

17.Crowther CA., Hiller JE., Doyle LW., Haslam RR. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgS04) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003. 290:2669–76.

18.Marret S., Marpeau L., Zupan-Simunek V., Eurin D., Leeue C., Hellot MF, et al. PREMAG Trial Group. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomized controlled PREMAG trial. BJOG. 2007. 114:310–8.

19.Marret S., Marpeau L., Follet-Bouhamed C., Cambonie G., Astruc D., Delaporte B, et al. PREMAG Trial Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn with two-year neurologic outcome: results of the prospective PREMAG trial. Gynecol Obstet Fertil. 2008. 36:278–88.

20.Rouse DJ., Hirtz DG., Thom E., Vamer MW., Spong CY., Mercer BM, et al. Eunice Kennedy Shriver NICHD Matemal-Fetal Medicine Units Network. A randomized trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008. 359:895–905.

21.Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomized trial comparing magnesium sulphate with placebo for preeclampsia. Outcome for children at 18 months. BJOG. 2007. 114:289–99.

22.Doyle LW., Crowther CA., Middleton P., Marret S., Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009. 1:CD004661.

23.Doyle LW. Antenatal magnesium sulfate and neuroprotection. Curr Opin Pediatr. 2012. 24:154–9.

24.Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks'gestation: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009. 200:595–609.

25.Food and Drug Administration. FDA recommends against prolonged use of magnesium sulfate to stop preterm labor due to bone changes in exposed babies. FDA Drug Safety Communication. Silver Spring (MD): FDA;2013. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM3533.pdf.

26.Amerian College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Matemal-Fetal Medicine. Committee opinion no. 573: Magnesium sulfate use in obstetrics. Obstet Gynecol. 2013. 122:727–8.